NEW YORK (GenomeWeb News) – The UK lab that is currently serving as an anti-doping testing facility for the 2012 Olympic and Paralympic games will be turned into a research center that will focus on phenomics-based disease studies.
Researchers from GlaxoSmithKline have sequenced 202 drug target genes in more than 14,000 individuals in order to look for variants that would suggest novel targets or a way to repurpose existing drugs.
This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).
Epizyme is hoping that its new partnership with Celgene International Sarl will bolster the development and commercialization of its pipeline of personalized treatments that inhibit histone methyltransferase enzymes associated with specific genetic alterations.